Proteinuria in Porcine Kidney Xenografts: Beyond Immunologic Failure

Kinoshita et al1 demonstrate prolonged porcine kidney xenograft survival under TNX-1500, but persistent nephrotic-range proteinuria remains a major limitation to long-term graft durability. The underlying mechanisms driving this functional incompatibility remain insufficiently defined, particularly as xenografts enter early clinical translation. We outline 3 concrete, actionable considerations to support mechanistic interpretation and future protocol optimization. First, interspecies differences in glomerular basement membrane composition, slit diaphragm architecture, and intraglomerular pressure may predispose porcine grafts to filtration barrier failure independent of immune injury.2 The study did not evaluate whether protective human transgenes, including hCD46, hCD55, and hCD47, are positioned in podocytes and fenestrated endothelium in a pattern that corresponds to nephrin, podocin, and vascular endothelial-cadherin. We recommend incorporating in situ hybridization, immunofluorescence colocalization, and ex vivo perfusion models to link transgene distribution with structural adaptation. Second, proteinuria introduces nonlinear, accelerated antibody clearance, distorting exposure-response relationships. Species differences in metabolic turnover, distribution volume, and neonatal Fc receptor affinity further between species further complicate fixed-dose strategies. A xenograft-specific pharmacokinetics–pharmacodynamics model that integrates serum trough levels, urinary antibody loss, albumin kinetics, and innate immune activation may help define effective exposure. Adaptive dosing informed by real-time clearance behavior could improve therapeutic precision. Third, quantification of urinary TNX-1500 by ELISA requires analytic validation in high-protein matrices. Viscosity, protease activity, and matrix interference may reduce antibody recovery and create misleading correlations. When the urine protein-to-creatinine ratio exceeds nephrotic thresholds or when serum trough levels fall unexpectedly, liquid chromatography–tandem mass spectrometry confirmation, spike-in recovery controls, and creatinine-normalized reporting should be implemented to ensure accuracy.3 We commend the authors for stimulating this critical dialogue as the field moves toward clinical translation. This landmark work advances immune regulation in kidney xenotransplantation but highlights proteinuria as a complex, multifactorial barrier encompassing structural incompatibility, pharmacologic instability, and analytic uncertainty. Addressing these dimensions will require not only enhanced transgene design and immune surveillance but also refined pharmacokinetics modeling, causal inference frameworks, and standardized biomarkers tailored to xenograft physiology.